Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phibro Animal HealthPAHC -3.41%75 PEG Ratio is 12.99 as of Aug. 08, 2026, which is 364% above its 10-year median of 2.80. GuruFocus rates PAHC with a GF Score™ of 75/100 and a GF Value™ of $29.54 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 349 Drug Manufacturers companies, Phibro Animal Health ranks worse than 91.69% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Phibro Animal Health's PEG Ratio or its related term are showing as below:
PAHC'
s PEG Ratio Range Over the Past 10 Years
Min: 1.17 Med: 2.8 Max: 20.21
Current: 13
During the past 13 years, Phibro Animal Health's highest PEG Ratio was 20.21. The lowest was 1.17. And the median was 2.80.
PAHC's PEG Ratio is ranked worse than 91.69% of 349
companies
in the Drug Manufacturers industry
Industry Median: 1.8
vs PAHC: 13.00
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Phibro Animal Health (NAS:PAHC) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Phibro Animal Health PEG Ratio Related Terms
Phibro Animal Health PEG Ratio Historical Data
* Premium members only.
The historical data trend for Phibro Animal Health's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phibro Animal Health PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Phibro Animal Health's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Phibro Animal Health (PAHC) has a PEG Ratio of 12.99 as of Aug. 08, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Phibro Animal Health and its competitors. This is 364% above median its historical median of 2.80. Over the past decade, Phibro Animal Health's PEG Ratio has ranged from 1.17 to 20.21. According to the industry distribution chart, Phibro Animal Health ranks #320 out of 349 companies in the Drug Manufacturers industry, placing it in the top 91.7%.
Is Phibro Animal Health's PEG Ratio too high?
Phibro Animal Health's current PEG Ratio of 12.99 is 364% above median its 10-year median of 2.80. Over the past 10 years, this metric has ranged from a low of 1.17 to a high of 20.21. The Drug Manufacturers industry median PEG Ratio is 1.80. Phibro Animal Health's value of 12.99 is 621.7% above this industry median. Based on the distribution chart, Phibro Animal Health ranks #320 out of 349 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Phibro Animal Health has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Phibro Animal Health's PEG Ratio compare to PRGO and HROW?
According to the Drug Manufacturers industry distribution chart, Phibro Animal Health ranks #320 out of 349 companies for PEG Ratio. This places Phibro Animal Health in the lower half of its industry. The industry median PEG Ratio is 1.80. Phibro Animal Health's value of 12.99 is 621.7% above this benchmark. Historically, Phibro Animal Health's own PEG Ratio has ranged from 1.17 to 20.21 over the past decade. While the company's 10-year median is 2.80 vs. the industry median of 1.80, Phibro Animal Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.80, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phibro Animal Health's current PEG Ratio of 12.99 is 621.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Phibro Animal Health and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phibro Animal Health's current PEG Ratio is 12.99, which is 364% above median its own 10-year median of 2.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phibro Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Phibro Animal Health (PAHC) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.54, compared to a current price of $34.26 — trading 16% above its estimated fair value. The current PEG Ratio is 12.99, which is 364% above median its 10-year median of 2.80 and 621.7% above the Drug Manufacturers industry median of 1.80. Phibro Animal Health's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Phibro Animal Health (PAHC), the current PEG Ratio is 12.99 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Phibro Animal Health (PAHC) Overvalued in 2026?
Based on GuruFocus' analysis, Phibro Animal Health stock appears to be overvalued.
The current stock price of $34.26 is trading 16% above its estimated GF Value™ of $29.54.
GuruFocus considers Phibro Animal Health to be Modestly Overvalued.
Key valuation signals for PAHC:
PEG Ratio: 12.99 (364% above median its 10-year median of 2.80)
GF Value™: $29.54 vs. price of $34.26 (16% above fair value)
Industry Position: 621.7% above the Drug Manufacturers median (#320 of 349)
No single metric tells the full story. See the PAHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
75GF Score
Get the complete analysis for PAHC
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PAHC has been successfully added to your 
